A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy
Oura, S.; Tanino, H.; Yoshimasu, T.; Sakurai, T.; Nakamura, T.; Kokawa, Y.; Matsuyama, K.; Naito, Y.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(4): 511-514
2001
ISSN/ISBN: 0385-0684 PMID: 11329786 Document Number: 530818
A 73-year-old woman underwent docetaxel therapy for lung metastasis from breast cancer after having received CAF therapy. Because of the progressive disease due to secondary resistance to docetaxel, the patient was given three courses of paclitaxel therapy (60 mg/m2, day 1, 8, 15 and 22, repeated every 6 weeks). The paclitaxel therapy brought about no adverse effects and a 51%-reduction in the size of the metastatic lung tumor (PR). Although the duration of the response to the paclitaxel therapy was limited to about one month due to progression of a brain metastasis, paclitaxel therapy may be effective against docetaxel-resistant breast cancer.